FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Xolair Approved for Reducing Allergic Reactions

[ Price : $8.95]

FDA approves a Novartis supplemental BLA for Xolair (omalizumab) for reducing allergic reactions related to accidental exposure to...

Metabolic Disease Panel Notice Amended

[ Price : $8.95]

Federal Register notice: FDA amends a 12/12/2023 notice requesting nominations for voting members to serve on CDERs Genetic Metabo...

Gilead Sciences Pauses Magrolimab Studies

[ Price : $8.95]

Gilead Sciences pauses enrollment globally in its magrolimab solid tumor studies and FDA subsequently requests (XXX TENSE XXX) a p...

CDRH Product Evaluation Head Maisel Retiring

[ Price : $8.95]

CDRH Office of Product Evaluation and Quality (OPEQ) director William Maisel announces he will retire this spring.

ANDA Product-Specific Guidances Added

[ Price : $8.95]

Federal Register notice: FDA is making available additional draft and revised draft product-specific guidances on the design of bi...

Fast Track for Type 1 Diabetes Drug

[ Price : $8.95]

FDA grants Diamyd Medical a fast-track designation for Diamyd (rhGAD65/alum) and its use in improving glycemic control in some dia...

Merit Medicals SCOUT Surgical Guide Cleared

[ Price : $8.95]

FDA clears a Merit Medical Systems 510(k) for the SCOUT MD Surgical Guidance System for use in implanting surgical reflectors in a...

Charging for Drugs Under an IND Guidance

[ Price : $8.95]

FDA makes available a final guidance entitled Charging for Investigational Drugs Under an IND: Questions and Answers.

FDA Digital Transformation Office Reorganization

[ Price : $8.95]

Federal Register notice: FDA announces that its Office of Digital Transformation has modified its organizational structure.

62 New or Revised Product-Specific Guidances Out

[ Price : $8.95]

FDA publishes for public comment 29 new and 33 revised product-specific guidances.